Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398784 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL439263 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL9679858 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL12398211 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL880199 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4651492 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL12087432 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL3917512 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL12371400 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL12087586 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016230-A1 | Salts of Prostaglandin Analog Intermediates | APOTEX INC. (CA) | 2018-01-18 | — | — | US | disclosed |
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | PTGIS, LSS, SQLE | RAB9A 3902/4885SMN1; SMN2 1146/4885KDM4E 3835/4885 |
| US-20180016230-A1 | Salts of Prostaglandin Analog Intermediates | PTGER1, PTGIS, PTGER3 | RAB9A 1980/4885SMN1; SMN2 3134/4885KDM4E 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.